NTNatera NTRA · NASDAQ
$436.00 +2.73% (+$11.58)
- Market cap
- $62.8B
- Enterprise value
- $62.0B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 23.2x
- P/FCF
- 876.6x
- EV/EBITDA
- -
- ROIC
- -10.0%
- Gross margin
- 65.3%
- Net margin
- -7.1%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.50
- Free float
- 93.6%
About the company
Natera, Inc. (NTRA) is an American biotechnology company specializing in the development and production of non-invasive genetic tests. With advanced technologies in reproductive medicine, oncology, and transplantation, Natera provides accurate and reliable tests for prenatal screening, detection of tumor markers, and transplant monitoring. The company is known for its focus on innovation and the use of advanced bioinformatics tools, enabling it to deliver high-quality genetic testing. Natera also collaborates with medical institutions and research organizations to enhance diagnostic capabilities. Natera, Inc. (NTRA) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on genetic testing and innovations in non-invasive diagnostics.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Steven Leonard Chapman
Employees
6,138
Headquarters
Austin
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 41% a year over the last 3 years.
- What speaks for it: Analysts expect revenue to grow by 26% this fiscal year.
- What to watch: It missed profit estimates 4 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $1.09B against $238.5M.
- What to watch: It passes only 3 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number